drugset
drugset / Trial / NCT03924245

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

NCT03924245 ↗

Phase 1 Terminated 3 enrolled Vanderbilt-Ingram Cancer Center AstraZeneca · collabSyndax Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase I/II trial studies the side effects and best dose of olaparib and entinostat and to see how well they work in treating patients with ovarian, primary peritoneal, or fallopian tube cancers that have come back or do not respond to platinum-based chemotherapy. Olaparib and entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2020-10-01
Primary completion
2022-02-04
Completion
2022-02-04

Outcome

Outcome not reported

Stopped: “Change in participant landscape and other treatment availability”

Drugs

EvaluationDrugModalityDoseRoute
Subject Entinostat Small molecule — Oral
Subject Olaparib Small molecule — Oral

Indications

fallopian tube carcinosarcoma fallopian tube clear cell adenocarcinoma fallopian tube endometrioid adenocarcinoma fallopian tube serous adenocarcinoma ovarian carcinosarcoma ovarian clear cell adenocarcinoma ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma primary peritoneal serous adenocarcinoma